English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/176246
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Cholinergic system and neuroinflammation: implication in multiple sclerosis

AuthorsDi Bari, Maria; Di Pinto, Giovanni; Reale, Marcella; Mengod Los Arcos, Guadalupe ; Tata, Ada Maria
KeywordsAcetylcholine
Cholinergic markers
Inflammation
Multiple sclerosis
Muscarinic receptors
Nicotinic receptors
Issue Date2017
PublisherBentham Science Publishers
CitationCentral Nervous System Agents in Medicinal Chemistry 17(2): 109-115 (2017)
Abstract[Background] Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system (CNS) characterized by leucocytes infiltration, demyelination, axonal degeneration and neuronal death. Although the etiology of MS is still unkwon, inflammation and autoimmunity are considered to be key players of the disease.
[Nervous System] The severe alterations affecting the nervous system contribute to the motor and cognitive disabilities and are in large part dependent on severe inflammatory processes active in both central nervous system and immune system. Acetylcholine (ACh) appears to be involved in the modulation of central and peripheral inflammation. Immune cells as well as astrocytes and microglia respond to ACh stimuli by activation of cholinergic receptors. Muscarinic and nicotinic receptors differently contribute to the modulation of immunological and inflammatory processes stimulating pro- and anti-inflammatory cytokines respectively. The role played by ACh in MS is not yet fully understood, although some results point to its involvement in different neurological disorders such as Alzheimer’s disease and schizophrenia.
[Conclusion] In the present review we summarize the evidence indicating the correlation between nervous system dysfunction in MS, with inflammation and cholinergic system alterations. Experiments performed in MS animal models and analyses on biological fluids from MS patients such as blood, serum and cerebrospinal fluid suggest that cholinergic alterations may contribute to the dysregulated inflammatory processes of MS. Many current therapeutic approaches in MS are based on anti-inflammatory drugs. We also discuss how the use of cholinesterase inhibitors or ACh mimetics may represent a new interesting therapeutic approach in MS.
Publisher version (URL)http://dx.doi.org/10.2174/1871524916666160822115133
URIhttp://hdl.handle.net/10261/176246
DOI10.2174/1871524916666160822115133
ISSN1871-5249
E-ISSN1875-6166
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.